CN1849323A - 作为抗病毒药的噻吩并吡咯 - Google Patents

作为抗病毒药的噻吩并吡咯 Download PDF

Info

Publication number
CN1849323A
CN1849323A CNA2004800257994A CN200480025799A CN1849323A CN 1849323 A CN1849323 A CN 1849323A CN A2004800257994 A CNA2004800257994 A CN A2004800257994A CN 200480025799 A CN200480025799 A CN 200480025799A CN 1849323 A CN1849323 A CN 1849323A
Authority
CN
China
Prior art keywords
pyrroles
thieno
cyclohexyl
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800257994A
Other languages
English (en)
Chinese (zh)
Inventor
B·阿滕尼
J·I·M·埃尔南多
S·马兰科纳
F·纳耶斯
J·M·安托里亚安托里亚
M·罗利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of CN1849323A publication Critical patent/CN1849323A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CNA2004800257994A 2003-09-09 2004-09-07 作为抗病毒药的噻吩并吡咯 Pending CN1849323A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0321003.6 2003-09-09
GBGB0321003.6A GB0321003D0 (en) 2003-09-09 2003-09-09 Compounds, compositions and uses

Publications (1)

Publication Number Publication Date
CN1849323A true CN1849323A (zh) 2006-10-18

Family

ID=29226699

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800257994A Pending CN1849323A (zh) 2003-09-09 2004-09-07 作为抗病毒药的噻吩并吡咯

Country Status (11)

Country Link
US (1) US7781431B2 (OSRAM)
EP (1) EP1664059B1 (OSRAM)
JP (1) JP2007505091A (OSRAM)
CN (1) CN1849323A (OSRAM)
AT (1) ATE373005T1 (OSRAM)
AU (1) AU2004270470A1 (OSRAM)
CA (1) CA2537545A1 (OSRAM)
DE (1) DE602004008945T2 (OSRAM)
ES (1) ES2291933T3 (OSRAM)
GB (1) GB0321003D0 (OSRAM)
WO (1) WO2005023819A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112752761A (zh) * 2018-08-21 2021-05-04 杏林制药株式会社 双环杂芳族环衍生物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200600424B (en) 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
GB0416396D0 (en) * 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
US7659263B2 (en) * 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
GB0509326D0 (en) 2005-05-09 2005-06-15 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2008001588A (es) 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
EP2079479B1 (en) 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2079480B1 (en) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
JP5352464B2 (ja) 2006-10-27 2013-11-27 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US20100099695A1 (en) 2006-10-27 2010-04-22 Liverton Nigel J HCV NS3 Protease Inhibitors
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CN103224506A (zh) 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
AU2008277442A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8126839B2 (en) * 2008-06-19 2012-02-28 Yahoo! Inc. Methods and apparatuses for adapting a ranking function of a search engine for use with a specific domain
BRPI0916235B8 (pt) 2008-07-22 2021-05-25 Merck Sharp & Dohme composto, composição farmacêutica, e, uso do composto ou da composição
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
US20110152243A1 (en) * 2009-12-23 2011-06-23 Abbott Laboratories Novel thienopyrrole compounds
CN105399697A (zh) * 2014-09-12 2016-03-16 苏州旺山旺水生物医药有限公司 一种氨基磺酰基类化合物、其制备方法及用途
EP3246330A1 (en) * 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
SU367098A1 (ru) * 1971-01-20 1973-01-23 Способ получения производных 4,5-диоксотиено- -
SU478833A1 (ru) * 1972-12-29 1975-07-30 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Способ получени производных тиено -(3,2-в)-пиррола
JPH04356029A (ja) 1990-07-02 1992-12-09 Japan Synthetic Rubber Co Ltd 非線形光学素子
JPH04179949A (ja) * 1990-11-15 1992-06-26 Fuji Photo Film Co Ltd 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2003212846A (ja) * 2001-06-26 2003-07-30 Japan Tobacco Inc 縮合環化合物及びｃ型肝炎治療剤
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1429759A4 (en) 2001-09-26 2004-12-15 Bristol Myers Squibb Co COMPOUNDS FOR TREATING HEPATITIS C VIRUS
GB0222909D0 (en) * 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
WO2004092158A1 (en) * 2003-04-17 2004-10-28 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112752761A (zh) * 2018-08-21 2021-05-04 杏林制药株式会社 双环杂芳族环衍生物
TWI811428B (zh) * 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
CN112752761B (zh) * 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物

Also Published As

Publication number Publication date
ATE373005T1 (de) 2007-09-15
CA2537545A1 (en) 2005-03-17
GB0321003D0 (en) 2003-10-08
ES2291933T3 (es) 2008-03-01
AU2004270470A1 (en) 2005-03-17
US7781431B2 (en) 2010-08-24
EP1664059A1 (en) 2006-06-07
JP2007505091A (ja) 2007-03-08
DE602004008945T2 (de) 2008-05-29
US20090036443A1 (en) 2009-02-05
WO2005023819A9 (en) 2006-03-23
EP1664059B1 (en) 2007-09-12
WO2005023819A1 (en) 2005-03-17
DE602004008945D1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
CN1849323A (zh) 作为抗病毒药的噻吩并吡咯
CN1079097C (zh) 杂二环磺胺衍生物和磺酸酯衍生物
CN1149209C (zh) 与多巴胺d3受体具有亲和力的三唑化合物
CN1144791C (zh) 三唑化合物及其作为多巴胺d3配体的应用
CN1254474C (zh) 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
CN1195762C (zh) 新的2－（亚氨基甲基）氨基－苯基衍生物、其制备、作为药物的应用以及含有它们的药物组合物
CN1051301C (zh) 吲哚酰基胍衍生物，其药物组合物及用途
CN1764641A (zh) 病毒聚合酶抑制剂
CN1170822C (zh) 咪唑化合物及其药物用途
CN1894258A (zh) 可用作蛋白激酶抑制剂的组合物
CN1070910A (zh) 新的噻唑基苯并呋喃衍生物，其制备方法及含该衍生物的药物组合物
CN1030252C (zh) 四氢苯并咪唑衍生物的制备方法
CN1764650A (zh) 2,3,6－三取代的－4－嘧啶酮衍生物
CN1922174A (zh) 病毒聚合酶抑制剂
CN1070173C (zh) 用作药物的苯甲酰基胍衍生物
CN1468217A (zh) 脂肪族含氮五员环化合物
CN1173497A (zh) 含杂环碳酸衍生物
CN1378533A (zh) 苯氧基丙胺类化合物
CN1055182A (zh) N-(吡咯并《2，3-d》嘧啶-3-基酰基)-谷氨酸衍生物
CN1491225A (zh) 三杂环化合物和包括其作为活性组分的药物
CN1100417A (zh) N-杂芳基-n＇-苯脲衍生物及其生产和应用
CN1313853A (zh) 作为生长激素释放剂的2－羟基吲哚衍生物
CN1297442A (zh) 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
CN1067053C (zh) 单环β－内酰胺类抗生素衍生物的中间体的制备方法
CN1780840A (zh) 吡唑并[1,5－a]嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication